Any current/future new fundraising through debt or equity?

There is no explicit mention of plans for new fundraising through debt or equity in the provided transcript. The company is currently in a high capex cycle, having spent around INR 185 crores in the first 9 months, with plans to spend up to INR 230-240 crores this financial year and INR 100-150 crores next year. The company has a high cash balance on its balance sheet (over INR 150 crores) and strong operating cash flows. The focus appears to be on utilizing internal accruals for ongoing capex and growth rather than raising new funds externally. The company is also looking at potential inorgan

Any current/future capex/capital investment/strategic investment?

In the first 9 months, Poly Medicure has spent around INR 185 crores on capex and expects to exceed this with a total of INR 230-240 crores for the full year. Four new plants: 2 already operational in Faridabad, 1 in Jaipur SEZ, and 1 under final stages of construction to be ready by early next financial year (April-May). Next year, additional capex of INR 100-150 crores planned to add more equipment and machines. New plants currently operating at 30-40% utilization; full ramp-up expected by end of the year. Capex focused on expanding manufacturing capacity for existing and new divisions such

Future growth expectations in sales/revenue/volumes?

The company targets a 20% growth in revenue for the next year, starting with a moderate estimate to revise upward after Q1 or early Q2. Domestic business is expected to grow around 22%-23%, driven by deeper market penetration and expansion of new divisions including renal, cardiology, and critical care. Renal segment projected to scale up sharply with an anticipated 50% growth next year, compared to 22% growth this year. Export business, especially Europe which accounts for ~40% of export revenues, is showing strong growth (40%+). US market entry underway with expected revenue buildup

Future growth expectations in earnings/operating earnings/profits/EPS?

For FY 2024-25, Poly Medicure Limited expects revenue growth of around 20%+, with a possibility of upward revision after Q1 or early Q2 based on actual performance. Domestic business aims to improve growth from 18.5% to about 22%-23% next year, driven by deeper market penetration and new divisions scaling up. Renal segment is expected to grow over 50% next year, rising from INR 90 crores to INR 140-145 crores, aided by regulatory traction and capacity expansion. Export business, especially Europe (40%+ of export revenue), continues to show strong growth (~35%-40%). EBITDA margin for the 9 mont

Current/ Expected Orderbook/ Pending Orders?

Poly Medicure Limited has contracts in place for the U.S. business and has started selling products there. The expected buildup in U.S. revenue is $15 million to $20 million annually by FY-28. The company is already sending initial shipments and receiving clinical feedback from U.S. customers. The company maintains a safety stock of raw materials covering 2 months to mitigate supply chain disruptions (e.g., Red Sea crisis). No specific current orderbook or pending order values were disclosed in exact terms during the call. The focus remains on scaling up shipments, product approvals, and expan

Poly Medicure LtdQ3 FY24Healthcare Equipment & Supplies

Poly Medicure Ltd Q3 FY24 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹1,638P/E: 54.6Market Cap: ₹17.5K CrSector: Healthcare Equipment & Supplies

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

The company targets a 20% growth in revenue for the next year, starting with a moderate estimate to revise upward after Q1 or early Q2.
Domestic business is expected to grow around 22%-23%, driven by deeper market penetration and expansion of new divisions including renal, cardiology, and critical care.
Renal segment projected to scale up sharply with an anticipated 50% growth next year, compared to 22% growth this year.
Export business, especially Europe which accounts for ~40% of export revenues, is showing strong growth (40%+).
US market entry underway with expected revenue buildup to $15-20 million annually by FY28.
Overall, exports have grown by ~23.5% in nine months, domestic by ~18.5%.
Increasing salesforce in India by ~100 people per year to boost productivity and coverage (5,000+ hospitals covered currently).
New manufacturing plants and capacity expansions aim for full utilization by year-end, supporting scaling volumes and revenue growth.

Margin guidance

Category 3

For FY 2024-25, Poly Medicure Limited expects revenue growth of around 20%+, with a possibility of upward revision after Q1 or early Q2 based on actual performance.
Domestic business aims to improve growth from 18.5% to about 22%-23% next year, driven by deeper market penetration and new divisions scaling up.
Renal segment is expected to grow over 50% next year, rising from INR 90 crores to INR 140-145 crores, aided by regulatory traction and capacity expansion.
Export business, especially Europe (40%+ of export revenue), continues to show strong growth (~35%-40%).
EBITDA margin for the 9 months stands near 26%, in line with guidance; operational leverage from new plants is expected to improve margins over coming years.
PAT has grown significantly (57% increase in 9 months) and is expected to maintain healthy growth consistent with revenue and margin expansion.

See what Poly Medicure Ltd management said on margin guidance — free account, 30 seconds.

Fundraise plans

There is no explicit mention of plans for new fundraising through debt or equity in the provided transcript.
The company is currently in a high capex cycle, having spent around INR 185 crores in the first 9 months, with plans to spend up to INR 230-240 crores this financial year and INR 100-150 crores next year.
The company has a high cash balance on its balance sheet (over INR 150 crores) and strong operating cash flows.
The focus appears to be on utilizing internal accruals for ongoing capex and growth rather than raising new funds externally.
The company is also looking at potential inorganic opportunities in the future, but no specific mention of equity or debt fundraising linked to those was made.

Order book

Poly Medicure Limited has contracts in place for the U.S. business and has started selling products there.
The expected buildup in U.S. revenue is $15 million to $20 million annually by FY-28.
The company is already sending initial shipments and receiving clinical feedback from U.S. customers.
The company maintains a safety stock of raw materials covering 2 months to mitigate supply chain disruptions (e.g., Red Sea crisis).
No specific current orderbook or pending order values were disclosed in exact terms during the call.
The focus remains on scaling up shipments, product approvals, and expanding market share across regions, including domestic and export markets.

See what Poly Medicure Ltd management said on order book — free account, 30 seconds.

Capex plans

Yes

In the first 9 months, Poly Medicure has spent around INR 185 crores on capex and expects to exceed this with a total of INR 230-240 crores for the full year.
Four new plants: 2 already operational in Faridabad, 1 in Jaipur SEZ, and 1 under final stages of construction to be ready by early next financial year (April-May).
Next year, additional capex of INR 100-150 crores planned to add more equipment and machines.
New plants currently operating at 30-40% utilization; full ramp-up expected by end of the year.
Capex focused on expanding manufacturing capacity for existing and new divisions such as renal, critical care, and cardiology.
Plans for setting up own gamma sterilization facility to reduce dependence on external vendors.
Looking at possible inorganic opportunities after current capex cycle tapers down.

Track Poly Medicure Ltd — get its next earnings analysis in your feed

How does Poly Medicure Ltd rank vs peers in Healthcare Equipment & Supplies?

Pro feature

ThisPoly Medicure Ltd

Rev 2Mar 3

See where Poly Medicure Ltd sits in Healthcare Equipment & SuppliesSee which companies these are, and every other name in the sector.Open rankings

How does Poly Medicure Ltd rank in Healthcare Equipment & Supplies?

Compare Poly Medicure Ltd against every Healthcare Equipment & Supplies company (Q3 FY24) on revenue, margins and earnings-call signals.

View Healthcare Equipment & Supplies leaderboard →

What Poly Medicure Ltd's management said in earlier quarters

Others in Healthcare Equipment & Supplies this season

Fischer Medical Ventures Ltd (Q2 FY25)
EBITDA: ₹36.3 crore, a 45.5% year-on-year increase. Key concall takeaways from Fischer Medical Ventures Ltd's Q2 FY25 earnings call — and how it ranks against…
Fischer Medical Ventures Ltd (Q1 FY27)
The provided pages of the investor presentation do not contain any specific revenue, sales, or volume figures for the quarter, nor details on year-on-year…
OSEL Devices Ltd (Q1 FY26)
FY25 total income (revenue) was ₹18,660.07 lakhs, up 41% YoY from ₹13,268.52 lakhs in FY24. Key concall takeaways from OSEL Devices Ltd's Q1 FY26 earnings call…
Q-Line Biotech Ltd (Q4 FY26)
Shift towards more manufacturing with gross margins of 60-65% for reagents supporting profitability improvement (Page 7, 6). Key concall takeaways from Q-Line…

Compare:vs Molbio Diagnosti vs Fischer Medical Ventures Ltd vs Tarsons Products

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →